Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02254239 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02254239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02254239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
February 4, 2016
Completion date
December 12, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hodgkin lymphoma, refractory hodgkin lymphoma